ABSTRACT
Objective: Real-world data for patients with endometrial cancer (EC) are limited, particularly in Latin America. We present treatment pattern findings from ECHOS-A - Endometrial Cancer Health Outcomes Study in Argentina. Materials and methods: A retrospective study using clinical data from privately insured patients with EC diagnosed from 2010 to 2019. Index (diagnosis proxy) was first date of an EC-related health term or treatment. Demographics, clinical characteristics, and FIGO staging were described. Disease progression and survival were assessed until study end, loss to follow-up, or death. Results: Of 805 patients with EC, 77.4 % (n = 623/805) received any treatment and 22.6 % (n = 182/805) received none. Among those treated, 31.8 % (n = 198/623) had first-line (1L) systemic therapy, and 45.5 % (n = 90/198) proceeded to second-line (2L) therapy. Mean follow-up was 33.6 (SD 31.8) months. Of those receiving any treatment, 87.3 % (n = 544/623) had FIGO stage data (I, 62.9 %; II, 18.6 %; III, 13.6 %; IV, 5.0 %). Treatment by class in 1L and 2L, respectively, were platinum chemotherapy, 73.7 %, 36.7 %; non-platinum chemotherapy, 73.7 %, 62.2 %; immunotherapy, 1.0 %, 11.1 %; hormone therapy, 17.7 %, 26.7 %. Carboplatin/paclitaxel was the most frequent 1L (52.5 %) and 2L (14.4 %) regimen. Mean time to progression was 14.1 (SD 16.3) and 8.8 (SD 8.3) months in 1L and 2L, respectively. Adjusted 1- to 5-year risk of progression/death was 46.5-77.5 % and 65.0-86.2 % in 1L and 2L, respectively. Conclusions: Approximately one-quarter of patients with EC received no treatment, and approximately two-thirds were not treated with 1L systemic therapy. Efforts to better understand the reasons for these treatment patterns are crucial for improving patient outcomes.
ABSTRACT
Introduction: Endometrial cancer is the second most frequent gynecological tumor in Argentina, representing 6% of all cancers in women. The objective of this study is to evaluate the oncological and perioperative results in patients with high-risk endometrial cancer (HREC) limited to the uterus, treated at the Hospital Italiano de Buenos Aires, between January 2010-2018. Methods: Retrospective cohort study that evaluated perioperative results, disease-free survival at 2, 4 years in patients with HREC. Results: Of a total of 123 patients, 74 met the inclusion criteria. Serous tumors were the most frequent histological type, n=38 (51%), while dedifferentiated tumors were the least frequent, n=2 (3%). Of all the patients included, 56 (76%) received at least one adjuvant treatment. Taxol platinum-based chemotherapy was implemented in 28 patients (38%), while 24 (33%) received a combination of chemotherapy and radiotherapy. The median follow-up time was 2.9 years. Disease-free survival in patients with stage IA at 2 and 4 years was 71% (95% CI 55-82) and 63% (CI 46-76), respectively, while those with stage IB were 53 (95% CI 33-70) and 38 (95% CI 19-58). Regarding the surgical approach, no significant differences were found in disease-free or overall survival when comparing the laparoscopic with the laparotomy approach (p=0.06). Conclusion: Only the FIGO stage showed an increased probability of death or relapse regardless of the type of adjuvant treatment and the type of surgery approach. Perioperative complications were similar in both approaches.
Introducción: En Argentina el cáncer de endometrio es el segundo tumor ginecológico más frecuente, representando el 6% de todos los cánceres en mujeres. El objetivo de este trabajo es evaluar los resultados oncológicos y perioperatorios, en pacientes con cáncer de endometrio de alto riesgo (CEAR) limitados al útero tratadas en el Hospital Italiano de Buenos Aires entre enero 2010-2018. Métodos: Estudio de cohorte retrospectivo que evaluó los resultados perioperatorios, la supervivencia libre de enfermedad a los 2, 4 años en pacientes con CEAR. Resultados: 74 pacientes cumplieron con los criterios de inclusión. Los tumores serosos fueron los más frecuente n=38 (51%), mientras que los desdiferenciados, los de menor frecuencia, n=2 (3%). 56 (76%) pacientes recibieron al menos un tratamiento adyuvante. El tratamiento sistémico fue implementado en 28 pacientes (38%), mientras que 24 (33%) recibieron una combinación de quimioterapia y radioterapia. La mediana de seguimiento fue de 2,9 años. La supervivencia libre de enfermedad, en pacientes con estadio IA a los 2 y 4 años fue de 71% (IC 95% 55-82) y 63 % (IC 46 -76) respectivamente, mientras que aquellas que presentaban un estadio IB fue de 53 (IC 95% 33-70) y 38 (IC 95% 19-58). En cuanto a la vía quirúrgica de abordaje, no se encontraron diferencias significativas en la supervivencia libre de enfermedad ni en las complicaciones perioperatorias. Conclusión: Sólo el estadio FIGO mostró un aumento en la probabilidad de muerte o recaída independientemente del tipo de tratamiento adyuvante realizado y de la vía de abordaje seleccionada.
Subject(s)
Endometrial Neoplasms , Humans , Female , Argentina/epidemiologyABSTRACT
Resumen Introducción : La extirpación del útero, (histerectomía) es la cirugía más frecuente en ginecología. En Argentina existen pocas publicaciones sobre los resultados perio peratorios de este tipo de procedimiento, y menos aún sobre histerectomía mínimamente invasiva. El objetivo de este estudio fue determinar la tasa de complica ciones perioperatorias en pacientes con histerectomía total laparoscópica realizada en el Hospital Italiano de Buenos Aires, desde el 7 de enero de 2010 al 22 de diciembre de 2020. Métodos : estudio de cohorte retrospectivo donde se revisaron las historias clínicas electrónicas de pacien tes sometidas a una histerectomía laparoscópica en el período mencionado. Se evaluaron las complicaciones intraquirúrgicas y postoperatorias utilizando la clasifi cación validada de Clavien-Dindo. Resultados : Se incluyeron 1014 pacientes. La tasa de complicaciones intraquirúrgicas fue de 4.5%. Se halló una tasa de complicaciones postoperatorias de 16.6% (n=168), siendo 12.3% (n=125) Clavien-Dindo ≤ 2, y 4.2% (n=43) Clavien-Dindo ≥ 3. En el análisis multivariable que se ajustó por peso uterino >170g, edad, índice de masa corporal y más de dos cirugías abdominales pre vias, se encontró asociación entre peso uterino > 170 g y complicaciones postoperatorias, OR 1.49, IC 95% 1.04- 2.14, p = 0.03. Discusión : Al evaluar el porcentaje de complicaciones menores y mayores, nuestros números se encuentran dentro de los parámetros aceptables para realizar este tipo de cirugía, más aún, considerando que la evaluación se realizó en un ámbito educativo.
Abstract Introduction : The removal of the uterus, (hysterec tomy), is the most frequent surgery in gynecology. In Argentina there are few publications on the periopera tive results of this type of procedure, and even less on minimally invasive hysterectomy. The objective of this study was to determine the rate of perioperative compli cations in patients with total laparoscopic hysterectomy performed at Hospital Italiano de Buenos Aires, from January 7, 2010 to December 22, 2020. Methods : retrospective cohort study where electronic medical records were reviewed. Intrasurgical and postop erative complications were evaluated using the validated Clavien-Dindo's classification. Results : 1014 patients were included. The rate of intra-surgical complications was 4.5%. In respect to postoperative complications, there was found a rate of 16.6% (n=168), being 12.3% (n=125) Clavien-Dindo ≤ 2, and 4.2% (n=43) Clavien-Dindo ≥ 3. In a multivariable analysis that adjusted for uterine weight > 170g, age, body mass index, and more than two previous abdomi nal surgeries, an association was found between uterine weight >170g and postoperative complications OR 1.49, 95% CI 1.04- 2.14, p=0.03. Discussion : When evaluating the percentage of mi nor and major complications, our findings are within the acceptable parameters for performing this type of surgery, even though the evaluation was carried out in an educational setting.
ABSTRACT
INTRODUCTION: The removal of the uterus, (hysterectomy), is the most frequent surgery in gynecology. In Argentina there are few publications on the perioperative results of this type of procedure, and even less on minimally invasive hysterectomy. The objective of this study was to determine the rate of perioperative complications in patients with total laparoscopic hysterectomy performed at Hospital Italiano de Buenos Aires, from January 7, 2010 to December 22, 2020. METHODS: retrospective cohort study where electronic medical records were reviewed. Intrasurgical and postoperative complications were evaluated using the validated Clavien-Dindo's classification. RESULTS: 1014 patients were included. The rate of intra-surgical complications was 4.5%. In respect to postoperative complications, there was found a rate of 16.6% (n=168), being 12.3% (n=125) Clavien-Dindo = 2, and 4.2% (n=43) Clavien-Dindo = 3. In a multivariable analysis that adjusted for uterine weight > 170g, age, body mass index, and more than two previous abdominal surgeries, an association was found between uterine weight >170g and postoperative complications OR 1.49, 95% CI 1.04- 2.14, p=0.03. DISCUSSION: When evaluating the percentage of minor and major complications, our findings are within the acceptable parameters for performing this type of surgery, even though the evaluation was carried out in an educational setting.
Introducción: La extirpación del útero, (histerectomía) es la cirugía más frecuente en ginecología. En Argentina existen pocas publicaciones sobre los resultados perioperatorios de este tipo de procedimiento, y menos aún sobre histerectomía mínimamente invasiva. El objetivo de este estudio fue determinar la tasa de complicaciones perioperatorias en pacientes con histerectomía total laparoscópica realizada en el Hospital Italiano de Buenos Aires, desde el 7 de enero de 2010 al 22 de diciembre de 2020. Métodos: estudio de cohorte retrospectivo donde se revisaron las historias clínicas electrónicas de pacientes sometidas a una histerectomía laparoscópica en el período mencionado. Se evaluaron las complicaciones intraquirúrgicas y postoperatorias utilizando la clasificación validada de Clavien-Dindo. Resultados: Se incluyeron 1014 pacientes. La tasa de complicaciones intraquirúrgicas fue de 4.5%. Se halló una tasa de complicaciones postoperatorias de 16.6% (n=168), siendo 12.3% (n=125) Clavien-Dindo = 2, y 4.2% (n=43) Clavien-Dindo = 3. En el análisis multivariable que se ajustó por peso uterino >170g, edad, índice de masa corporal y más de dos cirugías abdominales previas, se encontró asociación entre peso uterino > 170 g y complicaciones postoperatorias, OR 1.49, IC 95% 1.04-2.14, p = 0.03. Discusión: Al evaluar el porcentaje de complicaciones menores y mayores, nuestros números se encuentran dentro de los parámetros aceptables para realizar este tipo de cirugía, más aún, considerando que la evaluación se realizó en un ámbito educativo.
Subject(s)
Laparoscopy , Female , Humans , Cohort Studies , Retrospective Studies , Laparoscopy/adverse effects , Laparoscopy/methods , Hysterectomy/adverse effects , Hysterectomy/methods , Postoperative Complications/epidemiology , Postoperative Complications/etiologyABSTRACT
Objective: To report the surgical, oncological, and obstetrical outcomes of the different surgical techniques used for the fertility-sparing treatment of patients with early-stage cervical cancer. Methods: We retrospectively analyzed all fertility-sparing procedures performed between 2004 and 2020. The study included patients desiring to preserve fertility who had squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma histology, all grades, and FIGO 2009 stage IA2-IB1 tumors. Results: 48 patients met the inclusion criteria. Eight patients (16.7%) had stage IA2, and 40 (83.3%) had stage IB1 tumors. Conization with pelvic lymph node assessment was performed in 5 (10.4%) patients, an open radical trachelectomy in 21 (43.8%), and a laparoscopic radical trachelectomy in 22 (45.8%). No major intraoperative complications were registered. Two patients required surgery due to an early postoperative complication. Late postoperative complications were seen in 15 patients (31.2%), with cervical stenosis being the most frequent (60%). The rate of DFS at 2 and 5 years was 89% (95% CI, 76-95%), and the 5- year OS was 96% (95% CI, 83-98%). Univariate analysis demonstrated a relationship between tumor size and recurrence, but not for other prognostic tumor factors or surgical approach. One patient (4.8%) developed recurrent disease in the open radical trachelectomy group, and five (22.7%) in the laparoscopic radical trachelectomy group. The pregnancy rate was 41.4%, and the live birth rate 88.2%. Conclusion: Fertility-sparing treatment for patients with early-stage cervical cancer is ever-evolving. This study adds information to the literature about the outcomes of these quite uncommon procedures, and allows a critical analysis of many of the topics which are under discussion.
ABSTRACT
BACKGROUND: International guidelines recommend tailoring the radicality of hysterectomy according to the known preoperative tumor characteristics in patients with early-stage cervical cancer. OBJECTIVE: This study aimed to assess whether increased radicality had an effect on 5-year disease-free survival in patients with early-stage cervical cancer undergoing radical hysterectomy. The secondary aims were 5-year overall survival and pattern of recurrence. STUDY DESIGN: This was an international, multicenter, retrospective study from the Surveillance in Cervical CANcer (SCCAN) collaborative cohort. Patients with the International Federation of Gynecology and Obstetrics 2009 stage IB1 and IIA1 who underwent open type B/C1/C2 radical hysterectomy according to Querleu-Morrow classification between January 2007 and December 2016, who did not undergo neoadjuvant chemotherapy and who had negative lymph nodes and free surgical margins at final histology, were included. Descriptive statistics and survival analyses were performed. Patients were stratified according to pathologic tumor diameter. Propensity score match analysis was performed to balance baseline characteristics in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy. RESULTS: A total of 1257 patients were included. Of note, 883 patients (70.2%) underwent nerve-sparing radical hysterectomy, and 374 patients (29.8%) underwent non-nerve-sparing radical hysterectomy. Baseline differences between the study groups were found for tumor stage and diameter (higher use of non-nerve-sparing radical hysterectomy for tumors >2 cm or with vaginal involvement; P<.0001). The use of adjuvant therapy in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy was 27.3% vs 28.6%, respectively (P=.63). Five-year disease-free survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 90.1% (95% confidence interval, 87.9-92.2) vs 93.8% (95% confidence interval, 91.1-96.5), respectively (P=.047). Non-nerve-sparing radical hysterectomy was independently associated with better disease-free survival at multivariable analysis performed on the entire cohort (hazard ratio, 0.50; 95% confidence interval, 0.31-0.81; P=.004). Furthermore, 5-year overall survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 95.7% (95% confidence interval, 94.1-97.2) vs non-nerve-sparing 96.5% (95% confidence interval, 94.3-98.7), respectively (P=.78). In patients with a tumor diameter ≤20 mm, 5-year disease-free survival was 94.7% in nerve-sparing radical hysterectomy vs 96.2% in non-nerve-sparing radical hysterectomy (P=.22). In patients with tumors between 21 and 40 mm, 5-year disease-free survival was 90.3% in non-nerve-sparing radical hysterectomy vs 83.1% in nerve-sparing radical hysterectomy (P=.016) (no significant difference in the rate of adjuvant treatment in this subgroup, P=.47). This was confirmed after propensity match score analysis (balancing the 2 study groups). The pattern of recurrence in the propensity-matched population did not demonstrate any difference (P=.70). CONCLUSION: For tumors ≤20 mm, no survival difference was found with more radical hysterectomy. For tumors between 21 and 40 mm, a more radical hysterectomy was associated with improved 5-year disease-free survival. No difference in the pattern of recurrence according to the extent of radicality was observed. Non-nerve-sparing radical hysterectomy was associated with better 5-year disease-free survival than nerve-sparing radical hysterectomy after propensity score match analysis.
Subject(s)
Carcinoma, Squamous Cell , Uterine Cervical Neoplasms , Female , Pregnancy , Humans , Uterine Cervical Neoplasms/pathology , Retrospective Studies , Neoplasm Staging , Hysterectomy/adverse effects , Disease-Free Survival , Carcinoma, Squamous Cell/pathologyABSTRACT
Objective: Compare the perioperative outcomes and disease-free survival between minimally invasive and open surgery in women with stage I-II high-risk endometrial cancer. Methods: A retrospective, cohort study was performed involving twenty-four centers from Argentina. Patients with grade 3 endometrioid, serous, clear cell, undifferentiated carcinoma or carcinosarcoma who underwent hysterectomy, bilateral salpingo-oophorectomy, and staging between January 2010-2018 were included. Cox hazard regression analysis and Kaplan-Meier curves evaluated the association of surgical technique with survival. Results: Of 343 eligible patients, 214 (62 %) underwent open surgery and 129 (38 %) underwent laparoscopic surgery. No significant differences were seen between the two groups with respect to greater or equal grade III Clavien-Dindo postoperative complications (11 % in the open surgery group vs 9 % minimally invasive surgery group; P = 0.34) Minimally invasive surgery was not associated with worse disease-free survival at four years (79.14 % [95 % CI 69.42- 86.08] vs 78.80 % [95 % CI 70.61-84.96]), (p = 0.25), even after creating a Cox proportional model (hazard ratio [HR] 1.08 95 % CI 0.63-1.84); (p = 0.76). Conclusion: There was no difference between postoperative complications nor oncologic outcomes comparing minimally invasive and open surgery among patients with high-risk endometrial cancer.
ABSTRACT
OBJECTIVE: To evaluate the association of number of radical hysterectomies performed per year in each center with disease-free survival and overall survival. METHODS: We conducted an international, multicenter, retrospective study of patients previously included in the Surveillance in Cervical Cancer collaborative studies. Individuals with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IB1-IIA1 cervical cancer who underwent radical hysterectomy and had negative lymph nodes at final histology were included. Patients were treated at referral centers for gynecologic oncology according to updated national and international guidelines. Optimal cutoffs for surgical volume were identified using an unadjusted Cox proportional hazard model, with disease-free survival as the outcome and defined as the value that minimizes the P-value of the split in groups in terms of disease-free survival. Propensity score matching was used to create statistically similar cohorts at baseline. RESULTS: A total of 2,157 patients were initially included. The two most significant cutoffs for surgical volume were identified at seven and 17 surgical procedures, dividing the entire cohort into low-volume, middle-volume, and high-volume centers. After propensity score matching, 1,238 patients were analyzed-619 (50.0%) in the high-volume group, 523 (42.2%) in the middle-volume group, and 96 (7.8%) in the low-volume group. Patients who underwent surgery in higher-volume institutions had progressively better 5-year disease-free survival than those who underwent surgery in lower-volume centers (92.3% vs 88.9% vs 83.8%, P=.029). No difference was noted in 5-year overall survival (95.9% vs 97.2% vs 95.2%, P=.70). Cox multivariable regression analysis showed that FIGO stage greater than IB1, presence of lymphovascular space invasion, grade greater than 1, tumor diameter greater than 20 mm, minimally invasive surgical approach, nonsquamous cell carcinoma histology, and lower-volume centers represented independent risk factors for recurrence. CONCLUSION: Surgical volume of centers represented an independent prognostic factor affecting disease-free survival. Increasing number of radical hysterectomies performed in each center every year was associated with improved disease-free survival.
Subject(s)
Uterine Cervical Neoplasms , Humans , Female , Retrospective Studies , Uterine Cervical Neoplasms/pathology , Neoplasm Staging , Disease-Free Survival , Hospitals , Hysterectomy/methodsABSTRACT
OBJECTIVE: The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer. METHODS: We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in the international multicenter Surveillance in Cervical CANcer (SCCAN) study. RESULTS: Of 692 analyzed patients, 274 (39.6%) received no adjuvant treatment (AT-) and 418 (60.4%) received radiotherapy or chemoradiotherapy (AT+). The 5-year disease-free survival (83.2% and 80.3%; PDFS = 0.365) and overall survival (88.7% and 89.0%; POS = 0.281) were not significantly different between the AT- and AT+ groups, respectively. Adjuvant (chemo)radiotherapy was not associated with a survival benefit after adjusting for confounding factors by case-control propensity score matching or in subgroup analyses of patients with tumor size ≥4 cm and <4 cm. In univariable analysis, adjuvant (chemo)radiotherapy was not identified as a prognostic factor in any of the subgroups (full cohort: PDFS = 0.365; POS = 0.282). CONCLUSION: Among patients with IR early-stage cervical cancer, radical surgery alone achieved equal disease-free and overall survival rates to those achieved by combining radical surgery with adjuvant (chemo)radiotherapy.
Subject(s)
Uterine Cervical Neoplasms , Female , Humans , Uterine Cervical Neoplasms/pathology , Neoplasm Staging , Hysterectomy , Combined Modality Therapy , Prognosis , Radiotherapy, Adjuvant , Retrospective StudiesABSTRACT
BACKGROUND: In cervical cancer, presence of lymph-node macrometastases (MAC) is a major prognostic factor and an indication for adjuvant treatment. However, since clinical impact of micrometastases (MIC) and isolated tumor-cells (ITC) remains controversial, we sought to identify a cut-off value for the metastasis size not associated with negative prognosis. METHODS: We analyzed data from 967 cervical cancer patients (T1a1L1-T2b) registered in the SCCAN (Surveillance in Cervical CANcer) database, who underwent primary surgical treatment, including sentinel lymph-node (SLN) biopsy with pathological ultrastaging. The size of SLN metastasis was considered a continuous variable and multiple testing was performed for cut-off values of 0.01-1.0 mm. Disease-free survival (DFS) was compared between N0 and subgroups of N1 patients defined by cut-off ranges. RESULTS: LN metastases were found in 172 (18%) patients, classified as MAC, MIC, and ITC in 79, 54, and 39 patients, respectively. DFS was shorter in patients with MAC (HR 2.20, P = 0.003) and MIC (HR 2.87, P < 0.001), while not differing between MAC/MIC (P = 0.484). DFS in the ITC subgroup was neither different from N0 (P = 0.127) nor from MIC/MAC subgroups (P = 0.449). Cut-off analysis revealed significantly shorter DFS compared to N0 in all subgroups with metastases ≥0.4 mm (HR 2.311, P = 0.04). The significance of metastases <0.4 mm could not be assessed due to limited statistical power (<80%). We did not identify any cut-off for the size of metastasis with significantly better prognosis than the rest of N1 group. CONCLUSIONS: In cervical cancer patients, the presence of LN metastases ≥0.4 mm was associated with a significant negative impact on DFS and no cut-off value for the size of metastasis with better prognosis than N1 was found. Traditional metastasis stratification based on size has no clinical implication.
Subject(s)
Breast Neoplasms , Sentinel Lymph Node , Uterine Cervical Neoplasms , Female , Humans , Lymphatic Metastasis/pathology , Neoplasm Micrometastasis/pathology , Uterine Cervical Neoplasms/surgery , Uterine Cervical Neoplasms/pathology , Sentinel Lymph Node Biopsy , Lymph Nodes/pathology , Neoplasm Staging , Breast Neoplasms/pathology , Sentinel Lymph Node/pathologyABSTRACT
Las revistas piratas o depredadoras (predatory journals en inglés) son cada vez más frecuentes y sorprenden en su buena fe a investigadores/as que buscan publicar sus manuscritos. Este artículo presenta un caso de descubrimiento y demostración de publicación en una revista pirata y un conjunto de sugerencias para evitar este error, como un aporte a profesionales de ciencias de la salud que realizan actividades de investigación. El resultado de las investigaciones mostró que la revista European Journal of Gynaecological Oncology(EJGO) es una revista pirata: fundada en 1980, solo desde 2020 posee International Standard Serial Number (ISSN) digital: sus primeras editoras, hasta 2020, no trabajaban en el área disciplinar de la revista ni pudieron ser rastreadas en ORCID; su actual editor no responde correos; la dirección postal de la editorial es la misma de una empresa canadiense importadora de juguetes. Hasta 2021 no poseía una plataforma web para el envío del manuscrito sino se enviaba el trabajo a un correo electrónico genérico. A raíz de nuestras denuncias fue suspendida de Scopus (Scimago) y Clarivate (Web of Science). Cuando Clarivate forzó a EJGO a avisar a sus lectores que estaba suspendida, inmediatamente cambió su página web y la empresa editora. En síntesis, se muestra un caso real de publicación en una revista pirata, la detección y comprobación de que dicha revista efectivamente cae en esta categoría y el aporte de conceptos y definiciones para tener en cuenta a fin de evitar caer en este error. (AU)
Predatory journals are becoming more frequent every day and surprise researchers who seek to publish their manuscripts. This article presents a case of discovery and demonstration of publication in a predatory journal and a set of suggestions to avoid this error, in a contribution to the education of health science professionals. The result of the research showed that the European Journal of Gynaecological Oncology (EJGO) is a pirate journal: founded in 1980, it obtainthe digital International Standard Serial Number (ISSN) in 2020; its former editors, until 2020, do not work in the disciplinary area of the journal and could not be tracked in ORCID, the new editor did not respond any mail; the postal address of the publisher is the same as that of a Canadian toy import company. Until 2021, it did not have a web platform for sending the manuscript, but rather the work was sent to a generic email. As a result of our complaints, it was suspended from Scopus (Scimago) and Clarivate (Web of Science).When Clarivate forced EJGO to notify its readers that it was suspended, it immediately changed its website and publisher. In brief, a real case of publication in a predatory journal is shown, the detection and verification that this journal actually falls into this category and contribution of concepts and definitions to avoid falling into this error. (AU)
Subject(s)
Scientific Publication Ethics , Predatory Journals as Topic , Scholarly Communication/ethicsABSTRACT
BACKGROUND: Up to 26% of patients with early-stage cervical cancer experience relapse after primary surgery. However, little is known about which factors influence prognosis following disease recurrence. Therefore, our aims were to determine post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors for PR-DSS. METHODS: Data from 528 patients with early-stage cervical cancer who relapsed after primary surgery performed between 2007 and 2016 were obtained from the SCANN study (Surveillance in Cervical CANcer). Factors related to the primary disease and recurrence were combined in a multivariable Cox proportional hazards model to predict PR-DSS. RESULTS: The 5-year PR-DSS was 39.1% (95% confidence interval [CI] 22.7%-44.5%), median disease-free interval between primary surgery and recurrence (DFI1) was 1.5 years, and median survival after recurrence was 2.5 years. Six significant variables were identified in the multivariable analysis and were used to construct the prognostic model. Two were related to primary treatment (largest tumour size and lymphovascular space invasion) and four to recurrence (DFI1, age at recurrence, presence of symptoms, and recurrence type). The C-statistic after 10-fold cross-validation of prognostic model reached 0.701 (95% CI 0.675-0.727). Three risk-groups with significantly differing prognoses were identified, with 5-year PR-DSS rates of 81.8%, 44.6%, and 12.7%. CONCLUSIONS: We developed the robust model of PR-DSS to stratify patients with relapsed cervical cancer according to risk profiles using six routinely recorded prognostic markers. The model can be utilised in clinical practice to aid decision-making on the strategy of recurrence management, and to better inform the patients.
Subject(s)
Adenocarcinoma/mortality , Carcinoma, Adenosquamous/mortality , Carcinoma, Neuroendocrine/mortality , Carcinoma, Squamous Cell/mortality , Neoplasm Recurrence, Local/mortality , Uterine Cervical Neoplasms/mortality , Adenocarcinoma/pathology , Adenocarcinoma/physiopathology , Adenocarcinoma/therapy , Adult , Asymptomatic Diseases , Carcinoma, Adenosquamous/pathology , Carcinoma, Adenosquamous/physiopathology , Carcinoma, Adenosquamous/therapy , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/physiopathology , Carcinoma, Neuroendocrine/therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/physiopathology , Carcinoma, Squamous Cell/therapy , Chemotherapy, Adjuvant , Female , Humans , Hysterectomy , Lymph Nodes/pathology , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/physiopathology , Neoplasm Recurrence, Local/therapy , Neoplasm Staging , Prognosis , Proportional Hazards Models , Radiotherapy, Adjuvant , Survival Rate , Trachelectomy , Tumor Burden , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/physiopathology , Uterine Cervical Neoplasms/therapySubject(s)
Fertility Preservation/methods , Organ Sparing Treatments/methods , Ovary/surgery , Uterus/surgery , Adult , Female , Humans , Magnetic Resonance Imaging , Radiotherapy, Adjuvant/methods , Trachelectomy/methods , Uterine Cervical Neoplasms/diagnostic imaging , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/therapyABSTRACT
PURPOSE: Current guidelines for surveillance strategy in cervical cancer are rigid, recommending the same strategy for all survivors. The aim of this study was to develop a robust model allowing for individualised surveillance based on a patient's risk profile. METHODS: Data of 4343 early-stage patients with cervical cancer treated between 2007 and 2016 were obtained from the international SCCAN (Surveillance in Cervical Cancer) consortium. The Cox proportional hazards model predicting disease-free survival (DFS) was developed and internally validated. The risk score, derived from regression coefficients of the model, stratified the cohort into significantly distinctive risk groups. On its basis, the annual recurrence risk model (ARRM) was calculated. RESULTS: Five variables were included in the prognostic model: maximal pathologic tumour diameter; tumour histotype; grade; number of positive pelvic lymph nodes; and lymphovascular space invasion. Five risk groups significantly differing in prognosis were identified with a five-year DFS of 97.5%, 94.7%, 85.2% and 63.3% in increasing risk groups, whereas a two-year DFS in the highest risk group equalled 15.4%. Based on the ARRM, the annual recurrence risk in the lowest risk group was below 1% since the beginning of follow-up and declined below 1% at years three, four and >5 in the medium-risk groups. In the whole cohort, 26% of recurrences appeared at the first year of the follow-up, 48% by year two and 78% by year five. CONCLUSION: The ARRM represents a potent tool for tailoring the surveillance strategy in early-stage patients with cervical cancer based on the patient's risk status and respective annual recurrence risk. It can easily be used in routine clinical settings internationally.
ABSTRACT
Ovarian cancer represents the third gynecological cancer in frequency in Argentina. There is a lack of information on this pathology in our country regarding the treatment and evolution of patients who suffer it. The aim of this study was to evaluate the perioperative and oncological results in patients with advanced epithelial ovarian tumor. We present a retrospective cohort in which we evaluated disease-free survival and overall survival in patients with epithelial ovarian tumor treated at the Hospital Italiano de Buenos Aires between June 2009 and June 2017. Of 170 patients included in the study, 72 (42.4%) received primary debulking surgery (CCP), while 98 (57.6%) received neoadjuvant therapy and interval surgery (CI). The optimal cyto-reduction rate was 75% and 79% respectively. No differences were found in perioperative outcomes, or in severe complications between the two groups. The median disease-free survival in the CCP group was 2.5 years (95% CI 1.6-3.1) while in the CI group it was 1.4 (95% CI 1.2-1.7) p < 0.001. The median overall survival was 5.8 years in CPP, and 3.5 years in CI. Faced with a meticulous selection by a group of experts, patients with advanced ovarian cancer treated with CCP present better oncological results than those who received neoadjuvant therapy and CI.
El cáncer de ovario ocupa el tercer lugar en frecuencia entre los cánceres ginecológicos en Argentina. Existe un déficit de información de esta enfermedad en nuestro país respecto al tratamiento y evolución oncológica de las pacientes. El objetivo de nuestro trabajo fue evaluar los resultados perioperatorios y oncológicos, en pacientes con tumor epitelial de ovario con estadios avanzados. Presentamos una cohorte retrospectiva en la que se evaluó la supervivencia libre de enfermedad y la supervivencia global en pacientes con tumores epiteliales de ovario tratadas en el Hospital Italiano de Buenos Aires entre junio del 2009 a junio del 2017. De 170 pacientes incluidas en el estudio, 72 (42.4%) fueron tratadas con una cirugía de citorreducción primaria (CCP), mientras que 98 (57.6%) recibieron neoadyuvancia y luego cirugía del intervalo (CI). La tasa de citorreducción óptima fue de 75% y de 79% respectivamente. No se encontraron diferencias en los resultados perioperatorios, ni en las complicaciones graves entre ambos grupos. La mediana de SLE en el grupo de CCP fue de 2.5 años (IC 95% 1.6-3.1) mientras que en el grupo de CI fue de 1.4 (IC 95% 1.2-1.7) p < 0.001. La mediana de supervivencia global fue de 5.8 años en CCP, y de 3.5 años en CI. En pacientes adecuadamente seleccionadas la CCP presenta mejores resultados oncológicos a la neoadyuvancia y CI. La selección correcta de las pacientes para tratamiento primario es fundamental para definir la conducta terapéutica.
Subject(s)
Ovarian Neoplasms , Carcinoma, Ovarian Epithelial/pathology , Carcinoma, Ovarian Epithelial/therapy , Female , Hospitals , Humans , Neoadjuvant Therapy , Neoplasm Staging , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Retrospective Studies , Treatment OutcomeABSTRACT
Resumen El cáncer de ovario ocupa el tercer lugar en frecuencia entre los cánceres ginecológicos en Argentina. Existe un déficit de información de esta enfermedad en nuestro país respecto al tratamiento y evolución oncológica de las pacientes. El objetivo de nuestro trabajo fue evaluar los resultados perioperatorios y oncológicos, en pacientes con tumor epitelial de ovario con estadios avanzados. Presentamos una cohorte retrospectiva en la que se evaluó la supervivencia libre de enfermedad y la supervivencia global en pacientes con tumores epiteliales de ovario tratadas en el Hospital Italiano de Buenos Aires entre junio del 2009 a junio del 2017. De 170 pacientes incluidas en el estudio, 72 (42.4%) fueron tratadas con una cirugía de citorreducción primaria (CCP), mientras que 98 (57.6%) recibieron neoadyuvancia y luego cirugía del intervalo (CI). La tasa de citorreducción óptima fue de 75% y de 79% respectivamente. No se encontraron diferencias en los resultados perioperatorios, ni en las complicaciones graves entre ambos grupos. La mediana de SLE en el grupo de CCP fue de 2.5 años (IC 95% 1.6-3.1) mientras que en el grupo de CI fue de 1.4 (IC 95% 1.2-1.7) p < 0.001. La mediana de supervivencia global fue de 5.8 años en CCP, y de 3.5 años en CI. En pacientes adecuadamente seleccionadas la CCP presenta mejores resultados oncológicos a la neoadyuvancia y CI. La selección correcta de las pacientes para tratamiento primario es fundamental para definir la conducta terapéutica.
Abstract Ovarian cancer represents the third gynecological cancer in frequency in Argentina. There is a lack of information on this pathology in our country regarding the treatment and evolution of patients who suffer it. The aim of this study was to evaluate the perioperative and oncological results in patients with advanced epithelial ovarian tumor. We present a retrospective cohort in which we evaluated disease-free survival and overall survival in patients with epithelial ovarian tumor treated at the Hospital Italiano de Buenos Aires between June 2009 and June 2017. Of 170 patients included in the study, 72 (42.4%) received primary debulking surgery (CCP), while 98 (57.6%) received neoadjuvant therapy and interval surgery (CI). The optimal cyto-reduction rate was 75% and 79% respectively. No differences were found in perioperative outcomes, or in severe complications between the two groups. The median disease-free survival in the CCP group was 2.5 years (95% CI 1.6-3.1) while in the CI group it was 1.4 (95% CI 1.2-1.7) p < 0.001. The median overall survival was 5.8 years in CPP, and 3.5 years in CI. Faced with a meticulous selection by a group of experts, patients with advanced ovarian cancer treated with CCP present better oncological results than those who received neoadjuvant therapy and CI.
Subject(s)
Humans , Female , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Retrospective Studies , Treatment Outcome , Neoadjuvant Therapy , Carcinoma, Ovarian Epithelial/pathology , Carcinoma, Ovarian Epithelial/therapy , Hospitals , Neoplasm StagingSubject(s)
Colposcopy/methods , Fertility Preservation/methods , Leiomyosarcoma/surgery , Vaginal Neoplasms/surgery , Adult , Female , Humans , Leiomyosarcoma/diagnostic imaging , Leiomyosarcoma/pathology , Positron Emission Tomography Computed Tomography , Vaginal Neoplasms/diagnostic imaging , Vaginal Neoplasms/pathologyABSTRACT
INTRODUCTION: Recent evidence has shown adverse oncological outcomes when minimally invasive surgery is used in early-stage cervical cancer. The objective of this study was to compare disease-free survival in patients that had undergone radical hysterectomy and pelvic lymphadenectomy, either by laparoscopy or laparotomy. METHODS: We performed a multicenter, retrospective cohort study of patients with cervical cancer stage IA1 with lymph-vascular invasion, IA2, and IB1 (FIGO 2009 classification), between January 1, 2006 to December 31, 2017, at seven cancer centers from six countries. We included squamous, adenocarcinoma, and adenosquamous histologies. We used an inverse probability of treatment weighting based on propensity score to construct a weighted cohort of women, including predictor variables selected a priori with the possibility of confounding the relationship between the surgical approach and survival. We estimated the HR for all-cause mortality after radical hysterectomy with weighted Cox proportional hazard models. RESULTS: A total of 1379 patients were included in the final analysis, with 681 (49.4%) operated by laparoscopy and 698 (50.6%) by laparotomy. There were no differences regarding the surgical approach in the rates of positive vaginal margins, deep stromal invasion, and lymphovascular space invasion. Median follow-up was 52.1 months (range, 0.8-201.2) in the laparoscopic group and 52.6 months (range, 0.4-166.6) in the laparotomy group. Women who underwent laparoscopic radical hysterectomy had a lower rate of disease-free survival compared with the laparotomy group (4-year rate, 88.7% vs 93.0%; HR for recurrence or death from cervical cancer 1.64; 95% CI 1.09-2.46; P=0.02). In sensitivity analyzes, after adjustment for adjuvant treatment, radical hysterectomy by laparoscopy compared with laparotomy was associated with increased hazards of recurrence or death from cervical cancer (HR 1.7; 95% CI 1.13 to 2.57; P=0.01) and death for any cause (HR 2.14; 95% CI 1.05-4.37; P=0.03). CONCLUSION: In this retrospective multicenter study, laparoscopy was associated with worse disease-free survival, compared to laparotomy.